Evoke Pharma Inc's fundamentals are relatively very healthy, and its growth potential is high.Its valuation is considered fairly valued, ranking 101/159 in the Pharmaceuticals industry.Institutional ownership is very high.Over the past month, multiple analysts have rated it as Hold, with the highest price target at 18.00.In the medium term, the stock price is expected to trend up.Despite a very weak market performance over the past month, the company shows strong fundamentals and technicals.
Evoke Pharma Inc's Score
Industry at a Glance
Industry Ranking
101 / 159
Overall Ranking
255 / 4587
Industry
Pharmaceuticals
Support & Resistance
Relevant data have not been disclosed by the company yet.
Score Analysis
Current score
Previous score
Analyst Rating
Based on
1
analysts
Hold
Current Rating
18.000
Target Price
+250.19%
Upside Space
Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.
Evoke Pharma Inc Highlights
StrengthsRisks
Evoke Pharma, Inc. is a specialty pharmaceutical company focused on the development and commercialization of drugs to treat gastrointestinal disorders and diseases. It develops, commercializes and markets GIMOTI, a nasal spray formulation of metoclopramide, for the relief of symptoms associated with acute and recurrent diabetic gastroparesis in adults. Gimoti is a dopamine antagonist / mixed 5-HT3 antagonist / 5-HT4 agonist with pro-motility and anti-emetic effects, for the relief of symptoms associated with acute and recurrent diabetic gastroparesis. Gimoti offers systemic delivery by nasal spray administration. It has developed a nasal formulation of metoclopramide to provide its targeted patient population with recurrent symptoms of diabetic gastroparesis with a product that is systemically delivered as an alternative to the oral or intravenous routes of administration. The nasal formulation delivers metoclopramide to patients with delayed gastric emptying and/or frequent vomiting.
High Growth
The company's revenue has grown steadily over the past 3 years, averaging 308.56% year-on-year.
Growing
The company is in a growing phase, with the latest annual income totaling USD 10.25M.
Fairly Valued
The company’s latest PE is 0.00, at a medium 3-year percentile range.
Evoke Pharma, Inc. is a specialty pharmaceutical company focused on the development and commercialization of drugs to treat gastrointestinal disorders and diseases. It develops, commercializes and markets GIMOTI, a nasal spray formulation of metoclopramide, for the relief of symptoms associated with acute and recurrent diabetic gastroparesis in adults. Gimoti is a dopamine antagonist / mixed 5-HT3 antagonist / 5-HT4 agonist with pro-motility and anti-emetic effects, for the relief of symptoms associated with acute and recurrent diabetic gastroparesis. Gimoti offers systemic delivery by nasal spray administration. It has developed a nasal formulation of metoclopramide to provide its targeted patient population with recurrent symptoms of diabetic gastroparesis with a product that is systemically delivered as an alternative to the oral or intravenous routes of administration. The nasal formulation delivers metoclopramide to patients with delayed gastric emptying and/or frequent vomiting.
Ticker SymbolEVOK
CompanyEvoke Pharma Inc
CEOD'Onofrio (Matthew J)
Websitehttps://evokepharma.com/
FAQs
What is the current price of Evoke Pharma Inc (EVOK)?
The current price of Evoke Pharma Inc (EVOK) is 11.000.
What is the symbol of Evoke Pharma Inc?
The ticker symbol of Evoke Pharma Inc is EVOK.
What is the 52-week high of Evoke Pharma Inc?
The 52-week high of Evoke Pharma Inc is 10.990.
What is the 52-week low of Evoke Pharma Inc?
The 52-week low of Evoke Pharma Inc is 1.940.
What is the market capitalization of Evoke Pharma Inc?
The market capitalization of Evoke Pharma Inc is 18.95M.
What is the net income of Evoke Pharma Inc?
The net income of Evoke Pharma Inc is -5.35M.
Is Evoke Pharma Inc (EVOK) currently rated as Buy, Hold, or Sell?
According to analysts, Evoke Pharma Inc (EVOK) has an overall rating of Hold, with a price target of 18.000.
What is the Earnings Per Share (EPS TTM) of Evoke Pharma Inc (EVOK)?
The Earnings Per Share (EPS TTM) of Evoke Pharma Inc (EVOK) is -1.379.